scholarly journals Rapid and dramatic glucose‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma

2020 ◽  
Author(s):  
Motoyuki Igata ◽  
Yoshitaka Yagi ◽  
Satoko Hanatani ◽  
Masaji Sakaguchi ◽  
Norio Ishii ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetes Patient ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect

scholarly journals Fast‐acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose‐lowering effect compared with insulin aspart

2019 ◽  
Vol 21 (9) ◽  
pp. 2068-2075 ◽  
Author(s):  
Thomas R. Pieber ◽  
Eva Svehlikova ◽  
Martina Brunner ◽  
Inge B. Halberg ◽  
Karen Margrete Due Thomsen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Aspart ◽  
Initial Exposure ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Acting Insulin ◽  
Glucose Lowering Effect ◽  
Fast Acting

Prior meal enhances the plasma glucose lowering effect of exercise in type 2 diabetes

2001 ◽  
Vol 33 (8) ◽  
pp. 1259-1264 ◽  
Author(s):  
PAUL POIRIER ◽  
SAMANTHA MAWHINNEY ◽  
LUC GRONDIN ◽  
ANGELO TREMBLAY ◽  
TOM BRODERICK ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Plasma Glucose ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect

scholarly journals Glucose-Lowering Effect of Home-Delivered Therapeutic Meals in Patients with Type 2 Diabetes

2020 ◽  
Vol 21 (1) ◽  
pp. 46-54
Author(s):  
Jong Han Choi ◽  
Se Hee Min ◽  
Kyeong Hye Lim ◽  
Uoon Jeong Shin ◽  
Min-Seon Kim
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect

scholarly journals Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Masashi Shimoda ◽  
Maiko Miyoshi-Takai ◽  
Shintaro Irie ◽  
Akihito Tanabe ◽  
Atsushi Obata ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Hypoglycemic Agents ◽  
Baseline Hba1c ◽  
Glucose Lowering ◽  
Dipeptidyl Peptidase 4 ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Effective Group

Dipeptidyl peptidase-4 (DPP-4) inhibitors are often used all over the world and exert various beneficial effects including glucose-lowering effect in many subjects with type 2 diabetes. It is poorly understood, however, which factors are closely related with the durability of glucose-lowering effect by DPP-4 inhibitor. In this study, we examined retrospectively which factors could mainly influence the durability of DPP-4 inhibitor. We enrolled 212 participants with type 2 diabetes to whom DPP-4 inhibitor was administered for over 1 year without an addition or increase of other hypoglycemic agents. Age and baseline HbA1c level were significantly higher in the effective group than those in the ineffective group. The effective group had a tendency of smaller amounts of weight change, average total cholesterol, and average triglyceride compared with the ineffective group. Multiple logistic regression analysis showed that average triglyceride and baseline HbA1c were independent predictors associated with the durability of DPP-4 inhibitor. Moreover, an average triglyceride level contributed to the durability of DPP-4 inhibitor in the obese group (BMI ≥ 25 kg/m2) but not in the nonobese group (BMI < 25 kg/m2). These results suggest the importance of strict triglyceride management to maintain the durability of glucose-lowering effect by DPP-4 inhibitor, especially in obese subjects with type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document